Cited by 47Diabetes Treatment and ManagementDiabetes Management and ResearchPharmaceutical Practices and Patient Outcomes

Use and discontinuation of insulin treatment among adults aged 75 to 79 years with type 2 diabetes

Open access
Weiner, Jonathan Z., Gopalan, Anjali, Mishra, Pranita, Lipska, Kasia J., Huang, Elbert S., Laiteerapong, Neda, Karter, Andrew J., Grant, Richard W.·2019·JAMA Internal Medicine

Abstract

Importance: Among older individuals with type 2 diabetes, those with poor health have greater risk and derive less benefit from tight glycemic control with insulin. Objective: To examine whether insulin treatment is used less frequently and discontinued more often among older individuals with poor health compared with those in good health. Design, Setting, and Participants: This longitudinal cohort study included 21 531 individuals with type 2 diabetes followed for up to 4 years starting at age 75 years. Electronic health record data from the Kaiser Permanente Northern California Diabetes Registry was collected to characterize insulin treatment and glycemic control over time. Data were collected from January 1, 2009, through December 31, 2017, and analyzed from February 2, 2018, through June 30, 2019. Exposures: Health status was defined as good (<2 comorbid conditions or 2 comorbidities but physically active), intermediate (>2 comorbidities or 2 comorbidities and no self-reported weekly exercise), or poor (having end-stage pulmonary, cardiac, or renal disease; diagnosis of dementia; or metastatic cancer). Main Outcomes and Measures: Insulin use prevalence at age 75 years and discontinuation among insulin users over the next 4 years (or 6 months prior to death if <4 years). Results: Of 21 531 patients, 10 396 (48.3%) were women, and the mean (SD) age was 75 (0) years. Nearly one-fifth of 75-year-olds (4076 [18.9%]) used insulin. Prevalence and adjusted risk ratios (aRRs) of insulin use at age 75 years were higher in individuals with poor health (29.4%; aRR, 2.03; 95% CI, 1.87-2.20; P < .01) and intermediate health (27.5%; aRR, 1.85; 95% CI, 1.74-1.97; P < .01) relative to good health (10.5% [reference]). One-third (1335 of 4076 [32.7%]) of insulin users at age 75 years discontinued insulin within 4 years of cohort entry (and at least 6 months prior to death). Likelihood of continued insulin use was higher among individuals in poor health (aRR, 1.47; 95% CI, 1.27-1.67; P < .01) and intermediate health (aRR, 1.16; 95% CI, 1.05-1.30; P < .01) compared with good health (reference). These same prevalence and discontinuation patterns were present in the subset with tight glycemic control (hemoglobin A1c <7.0%). Conclusions and Relevance: In older individuals with type 2 diabetes, insulin use was most prevalent among those in poor health, whereas subsequent insulin discontinuation after age 75 years was most likely in healthier patients. Changes are needed in current practice to better align with guidelines that recommend reducing treatment intensity as health status declines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2019.3759

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When older adults have an insulin plan with complexity beyond their self-management abilities, lowering the dose of insulin may not be adequate.

    “When older adults are found to have an insulin plan with complexity beyond their selfmanagement abilities, lowering the dose of insulin may not be adequate (99).”

    From 13. Older Adults: <i>Standards of Care in Diabetes—2024</i> (2024) · cites this paper as [99]

    The Discussion (page not provided) supports simplifying insulin regimens for some older adults to reduce hypoglycemia risk and make diabetes management more practical. It does not specifically discuss plans exceeding patients’ self-management abilities or say that lowering the insulin dose would be inadequate; the Limitations state that dose reductions could not be examined. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • When older adults have an insulin plan with complexity beyond their self-management abilities, lowering the dose of insulin may not be adequate.

    “When older adults are found to have an insulin plan with complexity beyond their selfmanagement abilities, lowering the dose of insulin may not be adequate (106).”

    From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [106]

    The Discussion (page unavailable) supports simplifying insulin regimens to address practical management needs and reduce hypoglycemia risk. It does not specifically address regimens exceeding patients’ self-management abilities, and the Limitations (page unavailable) state that insulin dose reductions could not be examined. Thus, the claim that lowering the dose may be inadequate is not established by this paper. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Deintensification of glucose-lowering plans can be achieved by either lowering the dose or discontinuing some medications, as long as individualized glycemic goals are maintained.

    “Deintensification of glucose-lowering plans can be achieved by either lowering the dose or discontinuing some medications, as long as individualized glycemic goals are maintained”

    From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [115]

    The Discussion (page unavailable in our copy) describes insulin discontinuation and regimen simplification, including moving from long- and short-acting insulin to long-acting insulin alone. It also discusses individualized glycemic treatment in older adults, but does not describe lowering medication doses or establish that individualized glycemic goals were maintained after deintensification. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. doi:10.1056/NEJMoa0802743 · DOI · Paper page
  2. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24): 2560-2572. doi:10.1056/NEJMoa0802987 · DOI · Paper page
  3. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251-258. doi:10.1001/jamainternmed. 2013.12956 · DOI · Paper page
  4. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care. 2015;38(1):22-28. doi:10.2337/dc14-1329 · DOI · Paper page
  5. Bruderer SG, Bodmer M, Jick SS, Bader G, Schlienger RG, Meier CR. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK: a nested case-control analysis. Diabetes Obes Metab. 2014; 16(9):801-811. doi:10.1111/dom.12282 · DOI · Paper page
  6. American Diabetes Association. 11. Older Adults: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(suppl 1):S119-S125. doi:10. 2337/dc18-S011 · DOI
  7. Moreno G, Mangione CM, Kimbro L, Vaisberg E; American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults With Diabetes Mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11):2020-2026. doi:10.1111/jgs.12514 · DOI
  8. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168(8):569-576. doi:10.7326/ M17-0939 · DOI
  9. Lee SJ. So much insulin, so much hypoglycemia. JAMA Intern Med. 2014;174(5):686-688. doi:10. 1001/jamainternmed.2013.13307 · DOI
  10. Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259-268. doi:10.1001/jamainternmed. 2013.12963 · DOI
  11. Arnold SV, Lipska KJ, Wang J, Seman L, Mehta SN, Kosiborod M. Use of intensive glycemic management in older adults with diabetes mellitus. J Am Geriatr Soc. 2018;66(6):1190-1194. doi:10. 1111/jgs.15335 · DOI · Paper page
  12. Sussman JB, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175(12):1942-1949. doi:10.1001/jamainternmed.2015.5110 · DOI · Paper page
  13. Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38(4): 588-595.
  14. Karter AJ, Schillinger D, Adams AS, et al. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the Diabetes Study of Northern California (DISTANCE). Diabetes Care. 2013;36(3): 574-579. doi:10.2337/dc12-0722 · DOI
  15. Messer LC, Laraia BA, Kaufman JS, et al. The development of a standardized neighborhood deprivation index. J Urban Health. 2006;83(6): 1041-1062. doi:10.1007/s11524-006-9094-x · DOI
  16. Stoddard PJ, Laraia BA, Warton EM, et al. Neighborhood deprivation and change in BMI among adults with type 2 diabetes: the Diabetes Study of Northern California (DISTANCE). Diabetes Care. 2013;36(5):1200-1208. doi:10.2337/dc11-1866 · DOI
  17. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/ 0003-4819-150-9-200905050-00006 · DOI · Paper page
  18. Campbell KH, Huang ES, Dale W, et al. Association between estimated GFR, health-related quality of life, and depression among older adults with diabetes: the Diabetes and Aging Study. Am J Kidney Dis. 2013;62(3):541-548. doi:10.1053/j.ajkd. 2013.03.039 · DOI
  19. Parker MM, Moffet HH, Adams A, Karter AJ. An algorithm to identify medication nonpersistence using electronic pharmacy databases. J Am Med Inform Assoc. 2015;22(5):957-961. doi:10.1093/ jamia/ocv054 · DOI
  20. Karter AJ, Moffet HH, Liu J, et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care. 2007;13(11):598-606.
  21. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738-747. doi:10.1111/bcp.12386 · DOI
  22. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827- 834. doi:10.1001/jamainternmed.2015.0324 · DOI
  23. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254-1268. doi:10.1111/bcp. 12732 · DOI
  24. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. doi:10.1136/bmjopen- 2014-006544 · DOI
  25. Anderson K, Foster M, Freeman C, Luetsch K, Scott I. Negotiating "unmeasurable harm and benefit": perspectives of general practitioners and consultant pharmacists on deprescribing in the primary care setting. Qual Health Res. 2017;27(13): 1936-1947. doi:10.1177/1049732316687732 · DOI
  26. Wallis KA, Andrews A, Henderson M. Swimming against the tide: primary care physicians' views on deprescribing in everyday practice. Ann Fam Med. 2017;15(4):341-346. doi:10.1370/afm.2094 · DOI
  27. Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the United States. JAMA Intern Med. 2018;178(12):1673- 1680. doi:10.1001/jamainternmed.2018.4720 · DOI
  28. Thompson W, Lundby C, Graabaek T, et al. Tools for deprescribing in frail older persons and those with limited life expectancy: a systematic review. J Am Geriatr Soc. 2019;67(1):172-180. doi: 10.1111/jgs.15616 · DOI
  29. Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176(7):1023-1025. doi:10.1001/jamainternmed. 2016.2288 · DOI · Paper page
  30. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(suppl 2):S151-S156. doi:10.2337/dc09-S301 · DOI · Paper page

Cited by

Sorted by citations

Authors
Weiner, J. Z., Gopalan, A., Mishra, P., Lipska, K. J., Huang, E. S., Laiteerapong, N., Karter, A. J., & Grant, R. W.
Affiliations
  • Kaiser Permanente (US)
  • Yale University (US)
  • University of Chicago (US)
Corresponding author
Weiner, Jonathan Z.
Venue
JAMA Internal Medicine
Published
2019-12-01
Volume
179
Issue
12
Pages
1633
ISSN
2168-6106 (ISSN-L)
OpenAlex
W2973253554
Cited by
47
References
5
Citations by year
2026: 5 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 10 · 2020: 7 · 2019: 2
FWCI
4.87
Type
journal article
Language
en
Open access
Locations
  • JAMA Internal Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001863)
  • National Institute on Aging (R56AG051683, R01AG063391)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24DK105340, K24DK109114, P30DK092949)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
type 2 diabetes, insulin therapy, insulin discontinuation, older adults, health status, comorbidities, glycemic control, tight glycemic control, frailty, end-stage organ disease, dementia, metastatic cancer, physical activity, mortality, Kaiser Permanente Northern California
MeSH terms
Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Longitudinal Studies, Male, Withholding Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review